Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SYNCAR-001 + STK-009 by Synthekine for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
SYNCAR-001 + STK-009 is under clinical development by Synthekine and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...
SYNCAR-001 + STK-009 by Synthekine for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
SYNCAR-001 + STK-009 is under clinical development by Synthekine and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....
SYNCAR-001 + STK-009 by Synthekine for Mantle Cell Lymphoma: Likelihood of Approval
SYNCAR-001 + STK-009 is under clinical development by Synthekine and currently in Phase I for Mantle Cell Lymphoma. According to...
SYNCAR-001 + STK-009 by Synthekine for Lupus Nephritis: Likelihood of Approval
SYNCAR-001 + STK-009 is under clinical development by Synthekine and currently in Phase I for Lupus Nephritis. According to GlobalData,...
STK-012 by Synthekine for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
STK-012 is under clinical development by Synthekine and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
STK-012 by Synthekine for Colorectal Cancer: Likelihood of Approval
STK-012 is under clinical development by Synthekine and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
SYNCAR-001 + STK-009 by Synthekine for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
SYNCAR-001 + STK-009 is under clinical development by Synthekine and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL)....